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The field of neuromuscular research has seen considerable recent advances in the
molecular and cellular understanding of muscle biology, and the treatment of neuromuscu-
lar disease. These advances are at the forefront of modern molecular methodologies, often
integrating across wet-lab cell and tissue models, dry-lab computational approaches, and
clinical studies. The continuing development and application of multiomics methods offer
particular challenges and opportunities, not least in the potential for personalized medicine.
More than 500 different genes are known to be associated with neuromuscular disorders [1],
and the identification of causative mutations has allowed the development of personalized
therapies [1,2]. However, even if great progress has been made during the last two decades
in different subgroups of neuromuscular disorders, there are still numerous challenges
to resolve, such as the optimization of therapeutic knock-down strategies [3], targeting
specific muscles and/or tissues of the nervous system [1], identifying genetic modifiers
that can impair a therapeutic strategy [2], targeting common pathways being affected
in different patient subgroups for a given disease [4,5], or understanding the impact of
neuromuscular disorders on other tissues that could be affected but may be understudied.
This Special Issue, entitled “Understanding Neuromuscular Health and Disease:
Advances in Genetics, Omics, and Molecular Function”, encompasses some 15 pub-
lications from colleagues working on a diverse range of neuromuscular diseases, in-
cluding Duchenne muscular dystrophy [6–9], facioscapulohumeral dystrophy [3,10,11],
amyotrophic lateral sclerosis [4,5,12], spinal muscular atrophy [2], Emery–Dreifuss mus-
cular dystrophy [13], and rheumatoid arthritis [14]. Looking across diseases, several
themes are recurrent, such as the efforts to identify genotype–phenotype correlations in
DMD [6,7,9] and ALS [4,5], the quest for effective biomarkers in many neuromuscular
conditions [2,8,10,14], and the use of genomic and multi-omic approaches towards better
ways to identify biomarkers and to understand disease [10,12,13].
The search for genotype–phenotype correlations can be aimed at the improved under-
standing of disease [4,5,7,9], but may also be relevant to potential therapeutic outcomes [6].
Of relevance to this Special Issue are genotype–phenotype correlations in DMD [6,7,9]
and in ALS [4,5]. It is interesting to contrast the state of these investigations in these
two conditions, differences which are related to the underlying genetics: DMD being due
to mutations at a single gene, and therefore correlations being sought between clinical
outcomes and specific mutation patterns within that gene [6,7,9]; ALS being a disease of
unclear aetiology for the majority of patients and the focus of these genotype–phenotype
investigations thus being on the relationship of different genes and their functional roles to
the implicated mechanisms [4] or clinical outcomes of the condition [5].
The use of genomics and multi-omics approaches is a theme which itself cuts across
the aims of current research, from the overlay of multiple omics data to achieve a global
perspective and new understanding of Emery–Dreifuss muscular dystrophy [13], to the
identification of novel circulating miRNA and protein biomarkers for FSHD using multi-
omics [10], through to the application of machine learning to the genomics of ALS, which
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is aimed at understanding the molecular basis of this disease (and is also relevant to
genotype–phenotype correlations) [12]. Deciphering the pathways and gene mutations
involved in neuromuscular diseases may allow for the development of computational
models helping our understanding of muscle pathologies, which could enable preclinical
studies of neuromuscular diseases in the context of personalized medicine [15].
Aside from therapeutic strategy development, the use of biomarkers may be critical as
disease trackers for the development of effective therapeutics (for example, in FSHD [10]),
but also to the personalized tailoring of existing treatments (in DMD [8], and in rheumatoid
arthritis [14]), and may prove useful in a broad sense for improved stratification, diagnosis,
and/or treatment (e.g., in adult SMA [2]).
We hope that studies such as these, that integrate modern molecular methodologies
across cell and tissue models, computational approaches, and clinical studies, will continue
to drive progress towards improved neuromuscular health and treatments for these often
severe diseases.
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